Projected Growth of the Global Extended-Release Drugs Market to Reach $111.26 Billion by 2029

Uncover key drivers, emerging technologies, and competitive movements shaping the extended-release drugs market from 2025–2034 with trusted insights from The Business Research Company

What CAGR And Valuation Are Anticipated For The Extended-Release Drugs Market By The End Of 2029?

The extended-release drugs market has seen rapid growth in recent years. It is forecast to increase from $63.11 billion in 2024 to $69.63 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 10.3%. This historical expansion can be attributed to several factors including better patient compliance, the prevalence of chronic diseases, enhanced efficacy, strategic patent protection, and the use of biodegradable implants.

The extended-release drugs market is projected to experience substantial expansion in the coming years. This market is set to reach $111.26 billion by 2029, achieving a compound annual growth rate (CAGR) of 12.4%. Factors contributing to this growth during the forecast period include personalized medicine approaches, patient-centric drug development, the increasing prevalence of lifestyle diseases, drug repurposing efforts, and broader global access to extended-release therapies. Key trends anticipated in the forecast period encompass pharmaceutical innovation, enhancements in drug delivery systems, breakthroughs in nanotechnology, the application of 3D printing in drug formulations, the utilization of artificial intelligence, and a focus on environmental sustainability.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12675&type=smp

Which Business Drivers Are Underpinning The Growth Of The Extended-Release Drugs Market?

The escalating prevalence of chronic health conditions is projected to propel the growth of the extended-release drug market moving forward. Chronic conditions are characterized as ailments lasting a year or longer, requiring ongoing medical care, restricting daily activities, or both. Heart disease, cancer, obesity, and diabetes serve as illustrative examples. Extended-release drug delivery systems are engineered to provide a relatively constant level of medication in the body over an extended duration. This approach helps maintain a consistent therapeutic effect and avoids the fluctuations in drug levels that can occur with immediate-release medications. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, it was estimated that by the year 2050, the number of individuals aged 50 years and older who have at least one chronic illness will surge by 99.5%, rising to 142.66 million. Consequently, the increasing incidence of chronic conditions is driving the growth of the extended-release drug market.

What Are The Principal Segment Types In The Extended-Release Drugs Market?

The extended-release drugs market covered in this report is segmented –

1) By Type: Sustained Release Drug, Controlled Release Drug

2) By Mode: Over-The-Counter, Prescription

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies, Drug Stores

Subsegments:

1) By Sustained Release Drug: Matrix Systems, Coating Systems

2) By Controlled Release Drug: Osmotic Systems, Microencapsulation Systems, Targeted Delivery Systems

How Are Industry Trends Steering The Expansion Of The Extended-Release Drugs Market?

A significant trend gaining traction within the extended-release drug market is product innovation. Leading corporations active in the extended-release drug market are focused on creating novel products to maintain their competitive standing. An example of this is Zydus Pharmaceuticals (USA) Inc., a generic pharmaceutical maker based in the US, which introduced Topiramate extended-release capsules for epilepsy in July 2022. The US Food and Drug Administration (USFDA) had earlier authorized the company to market Topiramate extended-release capsules, USP in 25 mg, 50 mg, and 100 mg dosages. This company holds the distinction of being the first in the nation to secure final approval and launch these specific extended-release capsules. Furthermore, Topiramate extended-release tablets have dual approvals for patients experiencing partial onset or primary generalized tonic-clonic seizures.

Which Companies Are Contributing Significantly To The Extended-Release Drugs Market Growth?

Major companies operating in the extended-release drugs market include Pfizer Inc., AbbVie Inc., Novartis AG, Sanofi SA, GlaxoSmithKline PLC, AstraZeneca Plc, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceuticals Inc., Eastman Chemical Company, Catalent Pharma Solutions Inc., Sun Pharmaceutical Industries Limited, Purdue Pharma LP, Amneal Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Mallinckrodt LLC, Allergan plc, Hisamitsu Pharmaceutical Co. Inc., Janssen Pharmaceuticals Inc., Noven Pharmaceuticals Inc., Mayne Pharma Group Ltd., Neos Therapeutics Inc., Ardena Holding NV, UPM Pharmaceuticals Inc., Oakwood Laboratories LLC, Roxane Laboratories Inc., Lavipharm Laboratories Inc., Watson Pharmaceuticals Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/extended-release-drugs-global-market-report

Which Region Offers The Most Opportunity For Extended-Release Drugs Market Expansion?

North America was the largest region in the extended-release drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the extended-release drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=12675&type=smp

Browse Through More Reports Similar to the Global Extended-Release Drugs Market 2025, By The Business Research Company

Extended Reality Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/extended-reality-global-market-report

Drugs Of Abuse Doa Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/drugs-of-abuse-doa-testing-global-market-report

Drugs For Benign Prostatic Hypertrophy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/drugs-for-benign-prostatic-hypertrophy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795